Copper Overload Kills Cancer Cells

Johannes Karges is researching compounds that kill tumor cells.
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Light-Activated Cuproptosis in Cancer Treatment

The Core Concept: Cuproptosis is a specific form of cell death triggered by an excess of intracellular copper. Utilizing this mechanism, researchers have developed a light-activated, copper-based agent complex embedded in polymeric nanoparticles that selectively targets and destroys cancer cells while preserving healthy tissue.

Key Distinction/Mechanism: Unlike conventional apoptosis pathways targeted by standard chemotherapy, cuproptosis is triggered when excess copper binds to mitochondrial proteins responsible for energy production, causing them to clump and inducing fatal cellular stress. To prevent damage to healthy cells, the highly toxic copper complex is encapsulated in polymeric nanoparticles that accumulate in tumors; a localized light stimulus is then used to sever a photo-responsive bond, selectively releasing the copper agent exclusively within the malignant tissue.

Major Frameworks/Components: 

• Targeted Metabolic Disruption: Exploits the altered, highly active metabolism of cancer cells, which naturally intake higher levels of copper compared to healthy tissue.
• Polymeric Nanoparticle Encapsulation: A specialized carrier system that safely transports the copper agent complex, preventing premature or uncontrolled release into the bloodstream.
• Photopharmacology and Photoactivated Chemotherapy (PACT): The integration of light-sensitive (photo-responsive) bonds within the basic polymer framework, requiring specific light radiation to dissolve the nanoparticles and achieve localized, highly controlled drug delivery.

Protein modification discovery opens cancer therapy possibilities

Purdue’s W. Andy Tao (front) and his associates have discovered a new type of modification on proteins from cancer-related mutation that holds potential as a therapeutic target. Three members of his group are co- authors of the study published in Nature Chemistry. From left are graduate students Yi-Kai Liu, Zhoujun Luo, and postdoctoral scientist Zheng Zhang.
Photo Credit: Purdue Agricultural Communications / Joshua Clark

Scientific Frontline: "At a Glance" Summary: Protein Modification and Cancer Therapy

• Main Discovery: Researchers identified a novel type of protein modification driven by mutations in the isocitrate dehydrogenase enzyme, which fundamentally alters how kinase enzymes regulate cellular energy and protein function during cancer development.
• Methodology: The research team analyzed normal cells, IDH1 mutant cells, and IDH1 mutant cells treated with anti-cancer drugs using polymer-based metal ion affinity capture to isolate and identify dozens of proteins modified by the metabolite D-2-hydroxyglutarate.
• Key Data: The targeted isocitrate dehydrogenase mutation is prevalent in over 70 percent of specific cancer types, including glioma, acute myeloid leukemia, and rare forms of liver cancer, directly causing an excessive accumulation of D-2-hydroxyglutarate.
• Significance: This study highlights a previously unrecognized chiral-dependent modification where metabolic byproducts exchange chemical signals through phosphorylation crosstalk, exposing a hidden mechanism that fuels tumor progression and metabolic reprogramming in fast-growing cancers.
• Future Application: The identification of these post-translational modifications provides a new framework for precision medicine, enabling the development of targeted therapeutics and advanced diagnostic imaging techniques specifically for cancers driven by isocitrate dehydrogenase mutations.
• Branch of Science: Biochemistry, Oncology, and Molecular Pharmacology.

New compounds to inactivate a key protein in the influenza virus

These new molecules can inhibit neuraminidase, one of the proteins that coats the influenza virus and a key target in many first-line treatments for both seasonal and pandemic influenza.Image Credit:University of Barcelona (NC-ND)

Scientific Frontline: Extended "At a Glance" Summary: Sugar-Derived Aziridines for Influenza Inhibition

The Core Concept: Researchers have designed a novel family of antiviral molecules—sugar-derived aziridines based on the structure of oseltamivir (Tamiflu)—that effectively bind to and inhibit neuraminidase, a key surface protein required for the spread of the influenza virus.

Key Distinction/Mechanism: Unlike current first-line flu treatments which act as reversible inhibitors, these new compounds initially mimic the enzyme’s transition state and subsequently form a covalent chemical bond with a key amino acid in the active site. This creates an irreversible block, permanently deactivating the enzyme and halting viral replication.

Major Frameworks/Components:

• Neuraminidase (NA) Targeting: Focusing on the specific viral surface enzyme responsible for enabling newly formed virus particles to detach from and exit infected host cells.
• Aziridine Ring Substitution: The structural modification of replacing the alkene group in standard oseltamivir with a highly configured aziridine ring to act as the primary reactive agent.
• Covalent Inhibition: The chemical mechanism ensuring permanent deactivation of the viral enzyme, overcoming the limitations and reversibility of traditional antiviral drugs.
• Computational Structural Biology: The utilization of atomic-level 3D modeling and computational methods to observe transition states and design the precise molecular structure of the inhibitors.

Photopharmacology: In-Depth Description

Photopharmacology is an emerging, highly precise branch of medicinal chemistry and pharmacology centered on the design and application of light-responsive drugs. Its primary goal is to achieve unprecedented spatiotemporal control over therapeutic agents. By utilizing specific wavelengths of light to activate or deactivate a drug, photopharmacology allows medical professionals to dictate exactly where in the body a drug acts (spatial control) and exactly when it is active (temporal control). This approach aims to maximize a drug's efficacy at the target site—such as a tumor or a localized infection—while keeping the drug entirely inert in healthy tissues, thereby eliminating severe systemic side effects.

Promising active substance against hepatitis E identified

Researchers have discovered a compound that prevents hepatitis E viruses from replicating. 
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Bemnifosbuvir as a Treatment for Hepatitis E

The Core Concept: Bemnifosbuvir is a synthetic nucleotide/nucleoside analogue, currently in clinical trials for hepatitis C, that has been identified as a highly effective inhibitor of the hepatitis E virus (HEV).

Key Distinction/Mechanism: The drug functions by providing "false building blocks" that mimic the natural structural components of viral genetic material. When the hepatitis E virus attempts to copy its genome, it incorporates these synthetic molecules, which successfully halts viral replication while leaving healthy host cells unharmed.

Major Frameworks/Components:

• Nucleotide/Nucleoside Analogues: The foundational pharmacological framework utilizing synthetic molecules structured similarly to DNA/RNA components to disrupt viral synthesis.
• Fluorescent Reporter Virus Screening: An in vitro screening methodology utilizing a modified virus carrying a fluorescent molecule, allowing researchers to visually monitor and quantify viral replication and its active inhibition.
• Preclinical Validation: The methodological progression from cellular assays to animal models to confirm both the compound's safety profile and its direct efficacy against HEV-induced liver inflammation.

Blood pressure-lowering drug with a light switch

Jörg Standfuss (left) and Quentin Bertrand are two of the researchers in the PSI Center for Life Sciences who now have found out, on the molecular level, why a light-controllable drug changes its potency.
Photo Credit: © Paul Scherrer Institute PSI/Markus Fischer

Scientific Frontline: Extended "At a Glance" Summary: Blood Pressure-Lowering Drug with a Light Switch

The Core Concept: Researchers have developed and observed a light-switchable blood pressure medication that alters its molecular shape and potency when exposed to specific wavelengths of light. This advancement allows the drug's therapeutic effects to be modulated with precise timing and localization within the body.

Key Distinction/Mechanism: Unlike standard beta blockers, the experimental drug photoazolol-1 contains an integrated azobenzene atomic group functioning as a synthetic light switch. When irradiated with violet light, this atomic group flips, changing the molecule from a straight to a bulkier, bent shape. While the molecule remains inside the binding pocket of the β-adrenergic receptor, its altered form binds less effectively, reducing its capacity to block adrenaline and dynamically altering the receptor's activity.

Origin/History: The switchable molecule was synthesized by collaboration partners at the Consejo Superior de Investigaciones Científicas in Barcelona. Its exact molecular transformation mechanisms were subsequently mapped by researchers at the Paul Scherrer Institute (PSI) using the SwissFEL X-ray free-electron laser, with the findings recently published in the journal Angewandte Chemie.

Novel cancer drug delivery system improves Paclitaxel absorption

Paclitaxel binding to L-PGDS
Improved solubility through hydrophobic bonds and CRGDK targeting peptides.
Image Credit: Osaka Metropolitan University

Scientific Frontline: Extended "At a Glance" Summary: Novel Cancer Drug Delivery System for Paclitaxel

The Core Concept: Researchers have developed a targeted drug delivery system (DDS) that utilizes the lipocalin-type prostaglandin D synthase (L-PGDS) enzyme as a carrier to efficiently solubilize and transport Paclitaxel, a heavy and poorly water-soluble anticancer drug, directly to cancerous tissues.

Key Distinction/Mechanism: Unlike conventional formulations that lose their efficacy shortly after administration ceases, this novel system maintains sustained antitumor effects. It functions by binding Paclitaxel via hydrophobic interactions to the β-barrel structure of the L-PGDS protein, which improves the drug's solubility by approximately 3,600-fold. Furthermore, a specialized targeting peptide (CRGDK) is attached to the protein, directing the drug specifically to neuropilin-1 receptors expressed on the surface of cancer cells rather than distributing it to healthy tissues.

Major Frameworks/Components: 

• Paclitaxel (PTX): An established, heavy-molecular-weight (854 Da) anticancer drug traditionally limited by its poor water solubility.
• L-PGDS Enzyme Carrier: The lipocalin-type prostaglandin D synthase protein used as a structural vehicle to house and transport the drug.
• Hydrophobic Interactions: The chemical mechanism allowing PTX to successfully bind to the upper region of the L-PGDS β-barrel.
• CRGDK Targeting Peptide: A specific peptide sequence attached to the C-terminus of L-PGDS that acts as a homing mechanism for neuropilin-1 receptors on cancer cells.

Researchers design a pioneering drug capable of reversing cognitive decline in Alzheimer’s disease in animal models

The study has been led by researchers from the Faculty of Pharmacy and Food Sciences at the University of Barcelona.
Photo Credit: Courtesy of University of Barcelona

Scientific Frontline: "At a Glance" Summary: Pioneering Drug for Alzheimer's Disease

• Main Discovery: Researchers have developed and validated an experimental compound, FLAV-27, capable of reversing cognitive decline in Alzheimer's disease by reprogramming the neuronal epigenome to correct altered gene expression rather than merely clearing amyloid plaques.
• Methodology: The team administered FLAV-27 to inhibit the G9a enzyme by blocking its access to S-adenosylmethionine, testing the drug's effects on epigenetic regulation across in vitro assays, C. elegans worms, and murine models of both early- and late-onset Alzheimer's disease.
• Key Data: While current monoclonal antibody treatments only slow cognitive decline by 27% to 35%, FLAV-27 restored functional cognition, social behavior, and synaptic structure in animal models while returning elevated peripheral biomarkers, including H3K9me2, SMOC1, and p-tau181, to normal baseline levels.
• Significance: The findings confirm that epigenetic dysregulation is a controllable mechanism linking major Alzheimer's pathologies such as neuroinflammation and tau accumulation, establishing a foundation for a new class of epigenetic disease-modifying therapies.
• Future Application: The compound will advance toward human clinical trials through regulatory toxicology studies, utilizing identified blood biomarkers to efficiently screen suitable patients and objectively monitor therapeutic efficacy via routine blood tests.
• Branch of Science: Neuropharmacology, Epigenetics, and Neuroscience.

Antibiotics can affect the gut microbiome for several years

Researchers have now collected a second sample from nearly half of the participants. The analyses are expected to reveal which effects remain after 16 years.
Photo Credit: Sandra Gunnarsson

Scientific Frontline: Extended "At a Glance" Summary: Long-Term Antibiotic Impact on the Gut Microbiome

The Core Concept: Antibiotic treatments can alter the composition and diversity of the bacterial community in the gastrointestinal tract, known as the gut microbiome, with measurable disruptions persisting for four to eight years after a single course of treatment.

Key Distinction/Mechanism: While the short-term disruptive effects of antibiotics on gut flora are well-documented, this research establishes the protracted nature of this ecological footprint. The mechanism of disruption varies significantly by antibiotic class; drugs such as clindamycin, fluoroquinolones, and the narrow-spectrum flucloxacillin cause substantial, long-lasting decreases in bacterial diversity, whereas commonly prescribed options like penicillin V result in only minor, transient changes.

Major Frameworks/Components: 

• Epidemiological Data Linkage: The methodology relies on cross-referencing longitudinal, individual-level pharmacy dispensing data with large-scale biobank microbiome mapping (utilizing Swedish population-based cohorts like SCAPIS and SIMPLER).
• Bacterial Diversity Reduction: The core metric for microbiome health in the study is the quantifiable decrease in the diversity of bacterial species present in the gut following exposure to specific antimicrobials.
• Antibiotic Stratification: The framework evaluates post-treatment recovery times by differentiating the ecological impact based on the specific spectrum and chemical class of the antibiotic administered.

New therapy approach for Leigh Syndrome

Microscopic image of a 3D brain model, as used in the study
(red: neural progenitor cells; blue: neurons).
Image Credit: © HHU / Stephanie Le, AG Prigione

Scientific Frontline: "At a Glance" Summary: Sildenafil as a Therapy for Leigh Syndrome

• Main Discovery: Researchers identified the repurposed drug Sildenafil as a highly promising and effective treatment capable of improving the disease course of Leigh Syndrome, a severe and previously untreatable mitochondrial disorder affecting brain energy metabolism.
• Methodology: The international research consortium derived induced pluripotent stem cells from patient skin cells to cultivate 3D brain organoids and nerve networks, subsequently utilizing these models to screen a comprehensive library of over 5,500 approved drugs and molecules.
• Key Data: Affecting roughly one in 36,000 live births, Leigh Syndrome had no approved treatments until this study screened 5,500 compounds and successfully administered the leading candidate, Sildenafil, to six human patients, all of whom demonstrated rapid recovery from critical episodes and increased muscular strength.
• Significance: Because Sildenafil already possesses a well-documented long-term safety profile for treating pulmonary hypertension in infants, this discovery bypasses standard early-phase toxicity hurdles, offering an immediate and safe therapeutic intervention for a fatal childhood neurodevelopmental disease.
• Future Application: The European Medicines Agency has officially granted Sildenafil an Orphan Drug Designation, enabling the SIMPATHIC research consortium to initiate a multinational, placebo-controlled clinical trial aimed at securing formal regulatory approval for widespread clinical use.
• Branch of Science: Pediatric Neurology, Cellular Biology, and Molecular Pharmacology.
• Additional Detail: The study represents the largest drug screening process ever conducted specifically for Leigh Syndrome, successfully overcoming the traditional lack of accurate cellular and animal models that historically hindered rare disease research.

Gene-based therapies poised for major upgrade thanks to Oregon State University research

Graphic depicts nanoparticles loaded with a genetic therapy entering a cell.
Image Credit: Courtesy of Oregon State University

Scientific Frontline: Extended "At a Glance" Summary: Advanced Lipid Nanoparticles for Gene Therapy

The Core Concept: A novel drug delivery methodology that utilizes optimized lipid nanoparticles to successfully transport genetic therapies and gene-editing tools into targeted sub-cellular compartments without being destroyed by the cell's natural waste disposal systems.

Key Distinction/Mechanism: Traditionally, many gene therapies are intercepted by lysosomes (the cell's recycling centers) and degraded before they can function. This new approach utilizes advanced ionizable lipids—which change their charge state depending on surrounding acidity—and a pioneering DNA-based barcoding system to measure, design, and select nanoparticle carriers that efficiently evade cellular destruction to release their genetic cargo.

Origin/History: The breakthrough findings were published in Nature Biotechnology on March 11, 2026. The research was spearheaded by graduate student Antony Jozić under the guidance of Professor Gaurav Sahay at the Oregon State University College of Pharmacy, in collaboration with researchers from OHSU, Tennessee Technological University, Yeungnam University (South Korea), and the University of Brest (France).

Medicinal cannabis may offer relief for endometriosis and pelvic pain

Photo Credit: Jeff W

Scientific Frontline: "At a Glance" Summary: Medicinal Cannabis for Endometriosis and Pelvic Pain

• Main Discovery: Cannabidiol oil, used alone or combined with dried cannabis flower, effectively reduces pain, improves sleep quality, and lowers anxiety in individuals suffering from endometriosis and related pelvic pain.
• Methodology: Researchers conducted a three-month prospective observational cohort study involving 28 participants diagnosed with endometriosis and/or pelvic pain. Participants were prescribed cannabidiol oil or a combination of the oil and dried cannabis flower, recording weekly pain scores on a 0-to-10 numerical scale and completing health profile questionnaires before and after the 12-week trial.
• Key Data: Overall pelvic pain scores decreased from an average of 5.4 to 3.7 out of 10. The severity of the worst pain experienced by participants dropped from an average of 7.6 to 5.3 out of 10, marking a clinically meaningful improvement in health-related quality of life.
• Significance: The study provides evidence for a well-tolerated, non-opioid alternative for managing complex endometriosis symptoms. The secondary benefits of reduced anxiety and improved sleep contributed to patient quality of life as significantly as the direct reduction in physical pain.
• Future Application: Large-scale clinical trials are required to establish standardized dosing, evaluate long-term safety, and identify specific patient profiles that will benefit most from medicinal cannabis as a primary or adjunct therapy for inflammatory pelvic conditions.
• Branch of Science: Gynecology and Pharmacology.
• Additional Detail: Participants reported that medicinal cannabis presented fewer and more manageable side effects compared to traditional opioid-based analgesics like tramadol, which frequently caused nausea, dizziness, and fatigue without providing consistent pain relief.

Early Alzheimer's increased connectivity lowered by cancer drug in the lab

Neurons exposed to amyloid-beta formed more connections (SSBs = single synaptic boutons), which could be lessened with cancer drug eFT508.
Image Credit: Figure reproduced from Wu et al. 2026

Scientific Frontline: Extended "At a Glance" Summary: Early Alzheimer's Hyperconnectivity and eFT508

The Core Concept: In the earliest stages of Alzheimer's disease, typically correlating with Mild Cognitive Impairment (MCI), low levels of the amyloid-beta protein induce an abnormal increase in neural connections (hyperconnectivity) prior to widespread cell death and memory loss.

Key Distinction/Mechanism: Challenging the traditional model that Alzheimer's begins primarily with synapse loss, this research demonstrates that the disease may actually initiate with too many poorly organized connections. Amyloid-beta rewires, rather than simply increases or decreases, cellular protein production, pushing neurons into an unstable state. The experimental cancer drug eFT508, which targets MAP kinase interacting kinase (MNK), successfully prevented this hyperconnectivity and restored normalized protein production in laboratory models.

Major Frameworks/Components:

• Amyloid-Beta Induced Synaptogenesis: Exposure to low doses of amyloid-beta over a short five-day period triggers hyperconnectivity and creates a self-reinforcing loop by upregulating the amyloid precursor protein.
• Expansion Microscopy: A state-of-the-art imaging technique that expands biological samples 5 to 6 times, enabling researchers to visualize and quantify individual synapses as small as 30 nanometers.
• Liquid-Chromatography Mass-Spectrometry: An analytical method used to profile internal neuronal changes, identifying 49 specific proteins whose production was altered by amyloid-beta exposure.
• MNK Inhibition (eFT508): The pharmacological mechanism utilized by the repurposed cancer drug to decrease neuroinflammation, inhibit abnormal protein synthesis, and restore approximately 70% of altered protein production.

Relax study by Dresden scientists: Innovative combination therapy shows promising efficacy in aggressive leukemia

Alongside his colleague Dr. Leo Ruhnke (right side), Prof. Christoph Röllig (left side) designed and supervised the RELAX study
Photo Credit: Courtesy of Dresden University

Scientific Frontline: "At a Glance" Summary: Acute Myeloid Leukemia Combination Therapy

• Main Discovery: The addition of the BCL2 inhibitor venetoclax to intensive chemotherapy substantially improves treatment outcomes for patients suffering from relapsed or refractory acute myeloid leukemia.
• Methodology: Researchers conducted a multicenter phase 1/2 clinical trial known as the RELAX study to evaluate the tolerability and efficacy of combining a standard chemotherapy regimen of cytarabine and mitoxantrone with venetoclax.
• Key Data: The experimental combination therapy achieved a 75 percent complete remission rate, representing a stark increase over the 40 percent remission rate historically observed with conventional chemotherapy alone.
• Significance: By effectively suppressing rapidly growing leukemia cells, this therapeutic approach successfully qualifies a significantly larger proportion of treatment-resistant patients for potentially curative stem cell transplantations.
• Future Application: The treatment regimen is currently undergoing expanded evaluation in over 150 additional patients and demonstrates strong potential to become the new standard of care for treating acute myeloid leukemia relapses.
• Branch of Science: Hematology, Oncology, and Clinical Pharmacology.
• Additional Detail: The therapeutic combination maintained high efficacy even against particularly resistant genetic variants of the disease, with the foundational findings formally published in The Lancet Haematology.

Blood clot sting in the tail of scorpion venom

Arabian fat-tailed scorpion (Androctonus crassicauda)
Photo Credit: Per-Anders Olsson
(CC BY-SA 4.0)
Changes made: Enhanced and enlarged by Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Procoagulant Properties of Fat-Tailed Scorpion Venom

The Core Concept: A recent study has revealed that the highly lethal, primarily neurotoxic venom of fat-tailed scorpions (genus Androctonus) possesses an additional, previously unknown biochemical mechanism that induces rapid blood clotting in humans.

Key Distinction/Mechanism: While the venom is known to overwhelm the nervous system to cause heart failure, it simultaneously exhibits a profound procoagulant effect by biochemically hijacking the human blood coagulation cascade. Specifically, the venom activates major clotting Factors VII and X—a process dependent on activated Factor V. Unlike the neurotoxic symptoms, this clotting activity is not neutralized by standard antivenoms, but can be blocked by specific small-molecule metalloprotease inhibitors.

Major Frameworks/Components:

• Dual-Action Pathology: The venom operates on two independent lethal pathways: neurotoxicity (nervous system overload) and procoagulation (abnormal blood clotting).
• Clotting Factor Activation: The venom's enzymes act with high precision on human physiology, specifically targeting and accelerating Factors VII and X.
• Adjunct Enzyme Inhibition: Testing revealed that the metalloprotease inhibitors marimastat and prinomastat successfully neutralize the venom's clotting effects, identifying the specific enzyme class responsible and proving the necessity of targeted adjunct therapies alongside traditional antivenom.

‘The munchies’ are real and could benefit those with no appetite

Carrie Cuttler, right, an associate professor in the Department of Psychology at WSU, points to a screen displaying data about caloric intake and THC, while Ryan McLaughlin, an associate professor in the Department of Integrative Physiology and Neuroscience in WSU’s College of Veterinary Medicine, looks on. Cuttler and McLaughlin co-direct The Health and Cognition (THC) Lab
Photo Credit: Ted S. Warren, College of Veterinary Medicine

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Cannabis consumption induces an acute cognitive appetite response, universally stimulating hunger independently of an individual's sex, age, weight, or prior food intake.
• Methodology: Researchers conducted a randomized clinical trial with 82 human volunteers who vaped either 20 milligrams of cannabis, 40 milligrams of cannabis, or a placebo, while parallel animal studies monitored food-seeking behavior in rats exposed to the drug.
• Key Data: Participants exposed to cannabis consumed significantly higher food volumes than the control group, displaying strong preferences for specific items like beef jerky and water even when previously satiated.
• Significance: The research confirms that appetite stimulation from tetrahydrocannabinol is strictly brain-mediated, occurring when the compound stimulates cannabinoid receptors in the hypothalamus to override natural satiety signals.
• Future Application: Findings provide a physiological foundation for developing targeted medicinal cannabis therapies to combat wasting syndromes and severe appetite loss in patients undergoing chemotherapy or managing chronic conditions like HIV and AIDS.
• Branch of Science: Neuroscience and Pharmacology
• Additional Detail: Pharmacology trials demonstrated that blocking cannabinoid receptors in the peripheral nervous system failed to curb appetite, whereas blocking identical receptors in the brain successfully suppressed the drug-induced hunger response.

Scientists unlock a massive new ‘color palette’ for biomedical research by synthesizing non-natural amino acids

Peptides have found use in over 80 drugs worldwide since insulin was first synthesized in the 1920s.
Image Credit: Scientific Frontline

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Researchers at UC Santa Barbara developed an efficient technique to synthesize non-natural amino acids that are immediately ready for direct use in peptide construction without extra modification steps.
• Methodology: The team utilized gold catalysis to generate stereoselective amino acids from inexpensive chemical ingredients, subsequently assembling them into peptides through a rinse-and-repeat process on a resin scaffold.
• Key Data: While lifeforms naturally utilize only 22 amino acids to build proteins, this breakthrough expands the available biochemical toolkit from a limited 22-molecule palette to potentially hundreds of noncanonical variations.
• Significance: The ability to easily incorporate non-natural amino acids allows drug designers to armor-plate peptide therapeutics against destructive bodily enzymes and force them into specific shapes for superior receptor binding.
• Future Application: Researchers plan to automate the synthesis process to provide non-chemists in drug development and materials research with accessible, low-friction access to these expanded molecular building blocks.
• Branch of Science: Biochemistry, Pharmacology, and Materials Science.
• Additional Detail: Unlike existing approaches that require complex manipulation, this method produces amino acids where the acid group is already primed to react, leaving only the amino group requiring unmasking.

Psychopharmacology: In-Depth Description

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, and behavior. It is an interdisciplinary field that merges the principles of neuroscience, pharmacology, and psychology to understand how chemical agents interact with the nervous system to alter mental states. Its primary goals are to elucidate the biological mechanisms of mental disorders and to develop effective pharmaceutical treatments to manage or cure these conditions.

Cancer treatment: optimization of CAR T-cell therapy

LMU physician Sebastian Kobold
Photo Credit: © LMU / Stephan Höck

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: An advanced form of immunotherapy in which Chimeric Antigen Receptor (CAR) T cells are genetically engineered to resist immunosuppressive signals found within solid tumors, enabling the immune system to effectively destroy cancer cells that were previously resistant to treatment.

Key Distinction/Mechanism: While standard CAR T-cell therapy is highly effective against blood cancers, it often fails against solid tumors because a metabolite called prostaglandin E2 (PGE2) suppresses the T cells' function. This new approach involves removing the specific receptors on the T cells that PGE2 binds to; by eliminating these binding sites, the T cells become "deaf" to the tumor's suppression signal and remain active to attack the malignancy.

Origin/History:

• 2024: Professor Sebastian Kobold’s research group at LMU University Hospital identifies that PGE2 blocks T cells in the tumor vicinity.
• 2026: The team, in cooperation with the University of Tübingen, publishes their success in engineering PGE2-resistant cells in Nature Biomedical Engineering.

Major Frameworks/Components:

• Chimeric Antigen Receptor (CAR) T Cells: Patient-derived immune cells modified to recognize specific cancer proteins (like CD19).
• Prostaglandin E2 (PGE2): An immunosuppressive metabolite in the tumor microenvironment that normally inhibits immune response.
• Receptor Knockout: The genetic removal of PGE2 receptors from T cells to prevent immunosuppression.

Established cancer drug reactivates immunotherapy

Professor Florian Bassermann and his team are researching the role of the ubiquitin system in cancer. Insights from their basic research are quickly benefiting patients as well.
Photo Credit: Kathrin Czoppelt / TUM Klinikum

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: Researchers have identified that an existing cancer drug, carfilzomib, can restore the efficacy of CAR-T cell therapy in multiple myeloma patients by preventing cancer cells from hiding their surface markers.

Key Distinction/Mechanism: A common resistance mechanism in immunotherapy involves cancer cells degrading specific surface antigens (like BCMA) via the ubiquitin-proteasome system, effectively becoming invisible to engineered T cells. Unlike therapies that require new drug discovery, this method utilizes carfilzomib—a known proteasome inhibitor—to block this degradation process, restabilizing the antigens on the cell surface and allowing the CAR-T cells to recognize and attack the cancer again.

Origin/History: The findings were published in the journal Blood in 2026 by a team led by Prof. Florian Bassermann and Dr. Leonie Rieger at the Technical University of Munich (TUM).

Major Frameworks/Components:

• CAR-T Cell Therapy: A treatment where a patient's T cells are genetically modified to target cancer cells.
• BCMA (B Cell Maturation Antigen): The specific protein target on multiple myeloma cells.
• Ubiquitin-Proteasome System: The intracellular network responsible for degrading proteins, identified here as the cause of BCMA loss.
• Carfilzomib: An approved drug that inhibits the proteasome, preventing antigen degradation.